1. Home
  2. TFPM vs ACAD Comparison

TFPM vs ACAD Comparison

Compare TFPM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TFPM
  • ACAD
  • Stock Information
  • Founded
  • TFPM 2016
  • ACAD 1993
  • Country
  • TFPM Canada
  • ACAD United States
  • Employees
  • TFPM N/A
  • ACAD N/A
  • Industry
  • TFPM Precious Metals
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • TFPM Industrials
  • ACAD Health Care
  • Exchange
  • TFPM Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • TFPM 4.3B
  • ACAD 3.8B
  • IPO Year
  • TFPM N/A
  • ACAD 2004
  • Fundamental
  • Price
  • TFPM $23.16
  • ACAD $22.54
  • Analyst Decision
  • TFPM Strong Buy
  • ACAD Buy
  • Analyst Count
  • TFPM 3
  • ACAD 18
  • Target Price
  • TFPM $23.67
  • ACAD $27.71
  • AVG Volume (30 Days)
  • TFPM 463.5K
  • ACAD 2.1M
  • Earning Date
  • TFPM 08-06-2025
  • ACAD 08-05-2025
  • Dividend Yield
  • TFPM 0.95%
  • ACAD N/A
  • EPS Growth
  • TFPM N/A
  • ACAD N/A
  • EPS
  • TFPM 0.02
  • ACAD 1.37
  • Revenue
  • TFPM $293,708,000.00
  • ACAD $996,283,000.00
  • Revenue This Year
  • TFPM $19.66
  • ACAD $13.28
  • Revenue Next Year
  • TFPM $0.85
  • ACAD $11.06
  • P/E Ratio
  • TFPM $929.82
  • ACAD $16.50
  • Revenue Growth
  • TFPM 39.01
  • ACAD 22.42
  • 52 Week Low
  • TFPM $13.94
  • ACAD $13.40
  • 52 Week High
  • TFPM $25.45
  • ACAD $25.23
  • Technical
  • Relative Strength Index (RSI)
  • TFPM 46.45
  • ACAD 59.56
  • Support Level
  • TFPM $22.70
  • ACAD $20.87
  • Resistance Level
  • TFPM $24.15
  • ACAD $23.12
  • Average True Range (ATR)
  • TFPM 0.68
  • ACAD 0.68
  • MACD
  • TFPM -0.15
  • ACAD 0.04
  • Stochastic Oscillator
  • TFPM 24.21
  • ACAD 75.32

About TFPM Triple Flag Precious Metals Corp.

Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: